Clinical Trial Update: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults [Phase 3]

View source ↗

Summary

Phase 3 study evaluating switching virologically suppressed HIV-1-infected adults from their current antiretroviral regimen to long-acting cabotegravir plus lon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Apretude (cabotegravir) (cabotegravir)
• RPV-LA (rilpivirine) (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-06-13